FOLH1 and posterior cortical atrophy: However, although EMBARK and PRESTO did not consider the addition of a PSMA PET, the currently accruing phase III RCT ARASTEP, which is comparing placebo to Darolutamide in high-risk BCR PCa patients, may help shed light on its use in this setting [12].